Open AccessPersonalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience
Author(s) -
Rouven Hoefflin,
Anna-Lena Geißler,
Ralph Fritsch,
Rainer Claus,
Julius Wehrle,
Patrick Metzger,
Meike Reiser,
Leman Mehmed,
Lisa Fauth,
Dieter Henrik Heiland,
Thalia Erbes,
Friedrich Stock,
Ágnes Csanádi,
Cornelius Miething,
Britta Weddeling,
Frank Meiß,
Dagmar von Bubnoff,
Christine Dierks,
Isabell Ge,
Volker Brass,
Steffen Heeg,
Henning Schäfer,
Martin Boeker,
Justyna Rawluk,
Elke Botzenhart,
Gian Kayser,
Simone Hettmer,
Hauke Busch,
Christoph Peters,
Martin Werner,
Justus Duyster,
Tilman Brummer,
Melanie Boerries,
Silke Laßmann,
Nikolas von Bubnoff
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00105
Subject(s) - medicine , personalized medicine , molecular diagnostics , oncology , cancer , precision medicine , targeted therapy , clinical trial , institutional review board , molecular biomarkers , population , intensive care medicine , bioinformatics , surgery , pathology , environmental health , biology
Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we report the 2-year experience of the Comprehensive Cancer Center Freiburg Molecular Tumor Board (MTB), one of the first interdisciplinary molecular tumor conferences established in Europe. The role of the MTB is to recommend personalized therapy for patients with cancer beyond standard-of-care treatment.